STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

CLGN files 6-K on Mayo Clinic’s 3D bioprinted skin using rhCollagen

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

CollPlant Biotechnologies (CLGN) filed a Form 6-K noting it issued a press release on October 16, 2025 titled “First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk.” The notice highlights Mayo Clinic researchers’ work and references CollPlant’s rhCollagen-based BioInk. No additional operational or financial details are included in this filing excerpt.

Positive

  • None.

Negative

  • None.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of October 2025

Commission File Number 001-38370

 

CollPlant Biotechnologies Ltd.

(Exact name of registrant as specified in its charter)

 

4 Oppenheimer St, Weizmann Science Park

Rehovot 7670104, Israel

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒     Form 40-F

 

 

 

 

 

On October 16, 2025, CollPlant Biotechnologies Ltd. issued a press release entitled “First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk”.

 

Attached hereto and incorporated by reference herein are the following exhibits:

 

99.1   Press Release, dated October 16, 2015

 

1

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  COLLPLANT BIOTECHNOLOGIES LTD.
       
Date: October 16, 2025 By: /s/ Eran Rotem
    Name: Eran Rotem
    Title: Deputy CEO and Chief Financial Officer

 

 

2

 

FAQ

What did CLGN disclose in this Form 6-K?

It disclosed the issuance of a press release titled “First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk.”

When was the press release issued by CollPlant (CLGN)?

October 16, 2025.

Who is credited with developing the 3D bioprinted human skin model?

Mayo Clinic researchers, as stated in the press release title.

What technology from CollPlant is referenced in the announcement?

CollPlant’s rhCollagen-based BioInk.

What is the form type of this submission?

Form 6-K.

What is CollPlant’s full company name?

CollPlant Biotechnologies Ltd.
Collplant Biotechnologies Ltd

NASDAQ:CLGN

CLGN Rankings

CLGN Latest News

CLGN Latest SEC Filings

CLGN Stock Data

26.83M
8.97M
10.16%
12.23%
0.33%
Biotechnology
Healthcare
Link
Israel
Rehovot